Project
A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant non-small cell lung carcinoma with acquired resistance ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant non-small cell lung carcinoma
Completed - recruitment closed · 2020 until 2028
Frueh Martin, Breuss Kim, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Completed - recruitment closed
Start Date
2020
End Date
2028
Financing
Industry
Labels
lung cancer